Literature DB >> 2164085

hCGRP8-37, a calcitonin gene-related peptide antagonist revealing calcitonin gene-related peptide receptor heterogeneity in brain and periphery.

T Dennis1, A Fournier, A Cadieux, F Pomerleau, F B Jolicoeur, S St Pierre, R Quirion.   

Abstract

The C-terminal fragment of human calcitonin gene-related peptide (CGRP), hCGRP8-37, fails to induce any biological activity in a variety of isolated tissues and behavioral assays even though it possesses nanomolar affinity for [125I]hCGRP alpha binding sites in the central nervous system and peripheral membrane preparations. However, hCGRP8-37 displays relatively potent, competitive antagonist properties toward the action of native hCGRP alpha in guinea pig atrial and ileal preparations and on the central nervous system-mediated inhibition of CGRP on food intake. On the contrary, in the rat vas deferens the antagonistic potency of hCGRP8-37 was much weaker and was ineffective against CGRP-induced hyperthermia after i.c.v. injection. Such evidence suggests the existence of at least two classes of CGRP receptors, the first (CGRP1) being sensitive to the antagonist properties of hCGRP8-37, whereas the second (CGRP2) is not. The use of hCGRP8-37 should greatly facilitate the characterization of the physiological roles of CGRP-like peptides, especially those which are mediated via the activation of CGRP1 receptors.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2164085

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  49 in total

1.  Receptors mediating CGRP-induced relaxation in the rat isolated thoracic aorta and porcine isolated coronary artery differentiated by h(alpha) CGRP(8-37).

Authors:  F M Wisskirchen; D W Gray; I Marshall
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

2.  CGRP and adrenomedullin binding correlates with transcript levels for calcitonin receptor-like receptor (CRLR) and receptor activity modifying proteins (RAMPs) in rat tissues.

Authors:  P Chakravarty; T P Suthar; H A Coppock; C G Nicholl; S R Bloom; S Legon; D M Smith
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

3.  Characterization of receptors for calcitonin gene-related peptide and adrenomedullin on the guinea-pig vas deferens.

Authors:  D R Poyner; G M Taylor; A E Tomlinson; A G Richardson; D M Smith
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

4.  Blockade and reversal of spinal morphine tolerance by peptide and non-peptide calcitonin gene-related peptide receptor antagonists.

Authors:  K J Powell; W Ma; M Sutak; H Doods; R Quirion; K Jhamandas
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

5.  CGRP receptors mediating CGRP-, adrenomedullin- and amylin-induced relaxation in porcine coronary arteries. Characterization with 'Compound 1' (WO98/11128), a non-peptide antagonist.

Authors:  P Hasbak; A Sams; S Schifter; J Longmore; L Edvinsson
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

6.  Receptor-activity-modifying protein 1 forms heterodimers with two G-protein-coupled receptors to define ligand recognition.

Authors:  K Leuthäuser; R Gujer; A Aldecoa; R A McKinney; R Muff; J A Fischer; W Born
Journal:  Biochem J       Date:  2000-10-15       Impact factor: 3.857

Review 7.  The pharmacology of adrenomedullin receptors and their relationship to CGRP receptors.

Authors:  Debbie L Hay; Alex C Conner; Stephen G Howitt; David M Smith; David R Poyner
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

8.  Spinal administration of lipoxygenase inhibitors suppresses behavioural and neurochemical manifestations of naloxone-precipitated opioid withdrawal.

Authors:  Tuan Trang; Maaja Sutak; Remi Quirion; Khem Jhamandas
Journal:  Br J Pharmacol       Date:  2003-08-26       Impact factor: 8.739

9.  CL/RAMP2 and CL/RAMP3 produce pharmacologically distinct adrenomedullin receptors: a comparison of effects of adrenomedullin22-52, CGRP8-37 and BIBN4096BS.

Authors:  D L Hay; S G Howitt; A C Conner; M Schindler; D M Smith; D R Poyner
Journal:  Br J Pharmacol       Date:  2003-08-26       Impact factor: 8.739

10.  Peptidergic modulation of synaptic transmission in the parabrachial nucleus in vitro: importance of degradative enzymes in regulating synaptic efficacy.

Authors:  T M Saleh; S B Kombian; J A Zidichouski; Q J Pittman
Journal:  J Neurosci       Date:  1996-10-01       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.